‘And Now for Your Entertainment . . . ’

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 1
Volume 7
Issue 1

WASHINGTON-Those were not your ordinary pop bands playing away at the DC Science Writers Association’s annual holiday bash at the National Academy of Sciences building.

WASHINGTON—Those were not your ordinary pop bands playing away at the DC Science Writers Association’s annual holiday bash at the National Academy of Sciences building.

The opening act billed itself as “The Directors.” And, indeed, they were, and all from the National Institutes of Health: Richard D. Klausner, MD, of the National Cancer Institute; Francis S. Collins, MD, PhD, of the National Human Genome Research Institute; and Stephen I. Katz, MD, PhD, of the National Institute of Arthritis and Musculoskeletal and Skin Diseases.

The evening also featured “Wild Type,” a musical ensemble of medical researchers from Johns Hopkins University, led by Bert Vogelstein, MD, professor of oncology. Both bands received a warm reception, but there was general agreement with one guest who suggested to one of the medicomusicians: “Don’t give up your day job.”

Recent Videos
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content